Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme

View ORCID ProfileMarie-Pierre Dubé, Olympe Chazara, Audrey Lemaçon, Géraldine Asselin, Sylvie Provost, Amina Barhdadi, Louis-Philippe Lemieux Perreault, Ian Mongrain, Quanli Wang, Keren Carss, Dirk S Paul, Jonathan W Cunningham, Jean Rouleau, Scott D Solomon, John J V McMurray, Salim Yusuf, Chris B Granger, Carolina Haefliger, Simon de Denus, View ORCID ProfileJean-Claude Tardif
doi: https://doi.org/10.1101/2021.09.28.21263908
Marie-Pierre Dubé
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
3Université de Montréal, Faculty of Medicine, Department of medicine, Université de Montréal, Montreal, Canada
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-Pierre Dubé
  • For correspondence: marie-pierre.dube{at}umontreal.ca jean-claude.tardif{at}icm-mhi.org
Olympe Chazara
4Centre for Genomics Research (CGR), Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Audrey Lemaçon
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
3Université de Montréal, Faculty of Medicine, Department of medicine, Université de Montréal, Montreal, Canada
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Géraldine Asselin
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Provost
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amina Barhdadi
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis-Philippe Lemieux Perreault
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Mongrain
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quanli Wang
4Centre for Genomics Research (CGR), Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keren Carss
4Centre for Genomics Research (CGR), Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk S Paul
4Centre for Genomics Research (CGR), Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan W Cunningham
5Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Rouleau
1Montreal Heart Institute, Montreal, Canada
3Université de Montréal, Faculty of Medicine, Department of medicine, Université de Montréal, Montreal, Canada
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott D Solomon
5Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John J V McMurray
6BHF Cardiovascular Research Centre University of Glasgow, Glasgow, UK
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salim Yusuf
7The Population Health Research Institute, Hamilton Health Sciences and the School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris B Granger
8Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Haefliger
4Centre for Genomics Research (CGR), Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon de Denus
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
9Université de Montréal, Faculty of Pharmacy, Montreal, Canada
B. Pharm Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Tardif
1Montreal Heart Institute, Montreal, Canada
3Université de Montréal, Faculty of Medicine, Department of medicine, Université de Montréal, Montreal, Canada
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-Claude Tardif
  • For correspondence: marie-pierre.dube{at}umontreal.ca jean-claude.tardif{at}icm-mhi.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Aims The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomised, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorised according to left ventricular ejection fraction and tolerability to an ACE inhibitor. We conducted a pharmacogenomic study of the CHARM studies to identify genetic predictors of heart failure progression and the efficacy and safety of treatment with candesartan.

Methods We performed genome-wide association studies (GWAS) with the composite endpoint of cardiovascular death or hospitalisation for heart failure in 2727 patients from CHARM-Overall and stratified by CHARM study according to preserved and reduced ejection fraction. The safety endpoints were hyperkalaemia, renal dysfunction, hypotension, and change in systolic blood pressure. We also conducted a genome-wide gene-level collapsing analysis from whole-exome sequencing data with the composite cardiovascular endpoint.

Results We found the genetic variant rs66886237 at 8p21.3 near the gene GFRA2 to be associated with the composite cardiovascular endpoint in 1029 HF patients with preserved ejection fraction from the CHARM-Preserved study [hazard ratio (HR): 1.91, 95% confidence interval (CI): 1.55-2.35; P=1.7×10-9], but not in patients with reduced ejection fraction. None of the GWAS for candesartan safety or efficacy passed the significance threshold.

Conclusions We have identified a candidate genetic variant potentially predictive of the progression of heart failure in patients with preserved ejection fraction. The findings require further replication and we cannot exclude the possibility that the results may be chance findings.

Competing Interest Statement

JCT reports a grant from AstraZeneca for the conduct of the study, and other grants from the Government of Quebec, the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH), the Montreal Heart Institute Foundation, Bill and Melinda Gates Foundation, Amarin, Esperion, Ionis, Servier, RegenXBio; personal fees from AstraZeneca, Sanofi, Servier; and personal fees and minor equity interest from Dalcor. JCT is author on patents "Methods of treating a coronavirus infection using Colchicine and Methods of treating a coronavirus infection using Colchicine" pending and a patent "Early administration of low-dose colchicine after myocardial infarction" pending assigned to the Montreal Heart Institute. MPD and JCT are authors on a patent "Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events" issued to Dalcor, no royalties received, a patent "Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent" issued to Dalcor, no royalties received, and a patent "Methods for using low dose colchicine after myocardial infarction", assigned to the Montreal Heart Institute. MPD reports personal fees and minor equity interest from Dalcor, other from AstraZeneca, GlaxoSmithKline, Pfizer, Servier, Sanofi. Olympe Chazara, Keren Carss, Dirk Paul, Quanli Wang, Carolina Haefliger report personal fees from AstraZeneca during the conduct of the study. Quanli Wang and Carolina Haefliger are stockholders of AstraZeneca. Funding for the exome sequencing of the CHARM cohort was provided by AstraZeneca. Simon de Denus was supported through grants from Pfizer, AstraZeneca, Roche Molecular Science, DalCor. Other authors have nothing to declare.

Clinical Trial

This is a post-hoc genetic substudy of registered trials: NCT00634309, NCT00634712, and NCT00634400

Funding Statement

This work was supported by an unrestricted research grant from AstraZeneca to JCT and the Montreal Heart Institute; and from the Health Collaboration Acceleration Fund from the Government of Quebec. JCT holds the Canada Research Chair in personalised medicine and the Universite de Montreal endowed research chair in atherosclerosis. MPD holds the Canada Research Chair in precision medicine data analysis. Simon de Denus holds the Universite de Montreal Beaulieu-Saucier Chair in Pharmacogenomics. JJVM is supported by a British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. JWC is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant T32HL094301.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Montreal Heart Institute research ethics committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data underlying this article cannot be shared publicly to preserve the privacy of study participants. The analytic methods and study materials may be made available to other researchers for purposes of reproducing the results or replicating the procedure. Summary statistics from the GWAS analyses are available publicly for visualisation and download at https://pheweb.statgen.org/charm

https://pheweb.statgen.org/charm

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
Marie-Pierre Dubé, Olympe Chazara, Audrey Lemaçon, Géraldine Asselin, Sylvie Provost, Amina Barhdadi, Louis-Philippe Lemieux Perreault, Ian Mongrain, Quanli Wang, Keren Carss, Dirk S Paul, Jonathan W Cunningham, Jean Rouleau, Scott D Solomon, John J V McMurray, Salim Yusuf, Chris B Granger, Carolina Haefliger, Simon de Denus, Jean-Claude Tardif
medRxiv 2021.09.28.21263908; doi: https://doi.org/10.1101/2021.09.28.21263908
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
Marie-Pierre Dubé, Olympe Chazara, Audrey Lemaçon, Géraldine Asselin, Sylvie Provost, Amina Barhdadi, Louis-Philippe Lemieux Perreault, Ian Mongrain, Quanli Wang, Keren Carss, Dirk S Paul, Jonathan W Cunningham, Jean Rouleau, Scott D Solomon, John J V McMurray, Salim Yusuf, Chris B Granger, Carolina Haefliger, Simon de Denus, Jean-Claude Tardif
medRxiv 2021.09.28.21263908; doi: https://doi.org/10.1101/2021.09.28.21263908

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3315)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13402)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5179)
  • Geriatric Medicine (482)
  • Health Economics (785)
  • Health Informatics (3285)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1198)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14656)
  • Intensive Care and Critical Care Medicine (915)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4953)
  • Nursing (262)
  • Nutrition (735)
  • Obstetrics and Gynecology (888)
  • Occupational and Environmental Health (797)
  • Oncology (2530)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1307)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (558)
  • Psychiatry and Clinical Psychology (4223)
  • Public and Global Health (7525)
  • Radiology and Imaging (1715)
  • Rehabilitation Medicine and Physical Therapy (1021)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (72)
  • Transplantation (237)
  • Urology (206)